Abcam, ab192466, Alexa Fluor® 647 Anti-Choline Acetyltransferase antibody [EPR13024(B)]

Size: 100µL
Rabbit Recombinant Monoclonal Choline Acetyltransferase antibody - conjugated to Alexa Fluor® 647. Suitable for IHC-P, ICC/IF and reacts with Human samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR13024(B),
Isotype:IgG,
Conjugation:Alexa Fluor® 647,
Excitation/Emission:Ex: 650nm, Em: 665nm,
Carrier free:No,
Reacts with:Human,
Applications:ICC/IF, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Preservative: 0.02% Sodium azideConstituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle, Stable for 12 months at -20°C, Store in the dark

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Choline Acetyltransferase (ChAT) also known as EC 2.3.1.6 acts as the enzyme responsible for synthesizing the neurotransmitter acetylcholine. It catalyzes the transfer of an acetyl group from acetyl-CoA to choline to form acetylcholine. ChAT is a protein with an approximate mass of 70 kDa and is expressed in cholinergic neurons throughout the central and peripheral nervous systems. High expression is observed in regions such as the basal forebrain and neuromuscular junctions which are important for cholinergic signaling.
Biological function summary
The enzyme plays an important role in cholinergic conduction by producing acetylcholine which functions in synaptic transmission. It does not function as part of a larger complex but its activity directly influences cholinergic synapses. Choline acetyltransferase function ensures the synthesis and availability of acetylcholine for release into the synaptic cleft initiating muscle contraction and modulating activity in the central nervous system.
Pathways
Choline acetyltransferase is critical in pathways governing neurotransmitter release such as the cholinergic synapse pathway. It interacts functionally with other proteins within this pathway including acetylcholinesterase which breaks down acetylcholine in the synaptic cleft. This interaction ensures proper neurotransmitter regulation and recycling maintaining synapse function and communication within neuronal circuits.
Alterations in choline acetyltransferase activity relate to neurological disorders including Alzheimer's disease and myasthenia gravis. In Alzheimer's disease reduced choline acetyltransferase function leads to decreased acetylcholine synthesis contributing to the cognitive decline observed in patients. In myasthenia gravis acetylcholine receptors are impaired but effective choline acetyltransferase activity is still necessary to manage neurotransmitter levels. A potential therapeutic angle involves targeting related proteins that exacerbate these conditions to support acetylcholine levels.